# Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemia

> **NCT04364269** · PHASE2 · COMPLETED · sponsor: **Vifor (International) Inc.** · enrollment: 35 (actual)

## Conditions studied

- Beta-Thalassemia
- Non-transfusion-dependent Thalassemia

## Interventions

- **DRUG:** VIT-2763 once a day (QD)
- **DRUG:** VIT-2763 twice a day (BID)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04364269
- **Lead sponsor:** Vifor (International) Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-11
- **Primary completion:** 2021-10-11
- **Final completion:** 2021-11-03
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2023-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04364269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04364269, "Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04364269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*